Story perspectives

Amgen's Uplizna: First FDA-Approved IgG4-RD Treatment

4/4/2025

35 2

Summary

Story summary

Amgen's Uplizna has made history by becoming the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory ailment impacting approximately 20,000 adults in the U.S. The groundbreaking MITIGATE trial revealed an impressive 87% reduction in flare risk, offering hope for those affected. Uplizna is also approved for neuromyelitis optica spectrum disorder and is under evaluation for generalized myasthenia gravis.

1 of 1

Story summary

Amgen's Uplizna has made history by becoming the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory ailment impacting approximately 20,000 adults in the U.S. The groundbreaking MITIGATE trial revealed an impressive 87% reduction in flare risk, offering hope for those affected. Uplizna is also approved for neuromyelitis optica spectrum disorder and is under evaluation for generalized myasthenia gravis.